Zepbound 7.5 mg/.5mL

Tirzepatide, the active ingredient in Zepbound, is a GIP/GLP-1 receptor agonist presented as a 7.5 mg/0.5 mL injection solution for subcutaneous use. It is indicated for chronic weight management in adults with obesity and in adults who are overweight with at least one weight-related comorbidity, as part of a comprehensive weight-management plan.[fda.gov]

GNH USA supplies Zepbound as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zepbound is a tirzepatide injection that acts on the GIP and GLP-1 pathways involved in appetite regulation and metabolic control.[fda.gov]

- Chronic weight management in adults with obesity: used as an adjunct to diet and physical activity in eligible adults.[fda.gov] - Chronic weight management in adults who are overweight with a weight-related comorbidity: used to support long-term weight management in qualifying patients.[fda.gov]

Zepbound can cause adverse reactions ranging from common gastrointestinal effects to less frequent serious events.[fda.gov]

Common Side Effects: - Nausea: one of the most frequently reported adverse reactions.[fda.gov] - Diarrhea: gastrointestinal intolerance may occur during treatment.[fda.gov] - Vomiting: can occur, particularly when treatment is initiated or adjusted.[fda.gov] - Constipation: reported among common digestive adverse effects.[fda.gov] - Abdominal pain: may occur as part of gastrointestinal tolerability issues.[fda.gov] Serious or Rare Side Effects: - Pancreatitis: acute pancreatitis has been reported with tirzepatide-class therapy.[fda.gov] - Gallbladder disease: gallbladder-related events may occur.[fda.gov] - Acute kidney injury from volume depletion: risk may increase with severe gastrointestinal losses.[fda.gov] - Hypersensitivity reactions: serious allergic reactions can occur.[fda.gov]

Zepbound requires standard injection safety and label-based precautions.[fda.gov]

- Verify contraindications: do not use in patients with a personal or family history of medullary thyroid carcinoma or in patients with MEN 2.[fda.gov] - Monitor for pancreatitis: stop and evaluate if severe, persistent abdominal pain occurs.[fda.gov] - Watch for dehydration: vomiting or diarrhea may lead to volume depletion and kidney problems.[fda.gov] - Use caution with diabetes medicines: the risk of hypoglycemia may increase when combined with insulin or insulin secretagogues.[fda.gov] - Review hypersensitivity history: serious allergic reactions require prompt medical attention.[fda.gov] - Store at 2-8°C: keep refrigerated, protect from light, do not freeze, and do not shake.[fda.gov]

Tirzepatide has clinically relevant interactions mainly through delayed gastric emptying and additive glucose-lowering effects.[fda.gov]

Major Interactions (Avoid): - Do not combine with other tirzepatide-containing products: duplicate therapy is not appropriate.[fda.gov] - Avoid use in patients with a history of severe hypersensitivity to tirzepatide: re-exposure may be dangerous.[fda.gov] Moderate Interactions (Monitor Closely): - Insulin: combined use may increase hypoglycemia risk and requires monitoring.[fda.gov] - Sulfonylureas: glucose-lowering effects may be additive, increasing hypoglycemia risk.[fda.gov] - Oral medications with narrow therapeutic windows: delayed gastric emptying may affect absorption of some oral drugs.[fda.gov] - Antidiabetic therapy overall: glucose monitoring may be needed when tirzepatide is started or changed.[fda.gov]